Medical Technology

@xconomy.com 3 years ago

FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats

@xconomy.com 3 years ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 4 years ago

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

@xconomy.com 4 years ago

Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B

@xconomy.com 4 years ago

FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades

@xconomy.com 4 years ago

Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds

@xconomy.com 4 years ago

Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More

@xconomy.com 4 years ago

Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More

@xconomy.com 5 years ago

At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments

@xconomy.com 5 years ago

FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take

@xconomy.com 5 years ago

Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More

@xconomy.com 5 years ago

Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues

@xconomy.com 5 years ago

Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug

@xconomy.com 5 years ago

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

@xconomy.com 5 years ago

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

@xconomy.com 5 years ago

Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More

@xconomy.com 5 years ago

Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision

@xconomy.com 5 years ago

Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines